Ibrutinib, a Bruton's tyrosine kinase inhibitor used for treatment of lymphoproliferative disorders, eliminates both aeroallergen skin test and basophil activation test reactivity

Journal of Allergy and Clinical Immunology

Volumn 140, Issue 3, 2017, Pages 875-879.e1

  Regan, Jennifer A ^a   Cao, Yun ^a   Dispenza, Melanie C ^a   Ma, Shuo ^a   Gordon, Leo I ^a   Petrich, Adam M ^a   Bochner, Bruce S ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALLERGEN; IBRUTINIB; ANTIALLERGIC AGENT; PROTEIN KINASE INHIBITOR; PYRAZOLE DERIVATIVE; PYRIMIDINE DERIVATIVE;

ALLERGY RAPID TEST; ARTICLE; BASOPHIL ACTIVATION TEST; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL TRIAL (TOPIC); FOOD AND DRUG ADMINISTRATION; HUMAN; IMMUNOREACTIVITY; LYMPHOPROLIFERATIVE DISEASE; MANTLE CELL LYMPHOMA; NEUTROPENIA; PRIORITY JOURNAL; SKIN TEST; WALDENSTROEM MACROGLOBULINEMIA; AGED; ANTAGONISTS AND INHIBITORS; BASOPHIL; DRUG EFFECT; IMMUNOLOGY; MALE; MIDDLE AGED;

AGAMMAGLOBULINAEMIA TYROSINE KINASE; AGED; ALLERGENS; ANTI-ALLERGIC AGENTS; BASOPHILS; HUMANS; LYMPHOPROLIFERATIVE DISORDERS; MALE; MIDDLE AGED; PROTEIN KINASE INHIBITORS; PYRAZOLES; PYRIMIDINES; SKIN TESTS;

EID: 85018674480     PISSN: 00916749     EISSN: 10976825     Source Type: Journal    
DOI: 10.1016/j.jaci.2017.03.013     Document Type: Article

References (9)

1. Gupta, R.S., Springston, E.E., Warrier, M.R., Smith, B., Kumar, R., Pongracic, J., et al. The prevalence, severity, and distribution of childhood food allergy in the United States. Pediatrics 128 (2011), 9–17.
2. Hata, D., Kawakami, Y., Inagaki, N., Lantz, C.S., Kitamura, T., Khan, W.N., et al. Involvement of Bruton's tyrosine kinase in FcεRI-dependent mast cell degranulation and cytokine production. J Exp Med 187 (1998), 1235–1247.
3. Byrd, J.C., Furman, R.R., Coutre, S.E., Flinn, I.W., Burger, J.A., Blum, K.A., et al. Targeting Btk with ibrutinib in relapsed chronic lymphocytic leukemia. N Engl J Med 369 (2013), 32–42.
4. Wang, M.L., Rule, S., Martin, P., Goy, A., Auer, R., Kahl, B.S., et al. Targeting Btk with ibrutinib in relapsed or refractory mantle-cell lymphoma. N Engl J Med 369 (2013), 507–516.
5. Treon, S.P., Tripsas, C.K., Meid, K., Warren, D., Varma, G., Green, R., et al. Ibrutinib in previously treated Waldenstrom's macroglobulinemia. N Engl J Med 372 (2015), 1430–1440.
6. Advanti, R.B., Buggy, J.J., Sharman, J.P., Smith, S.M., Boyd, T.E., Grant, B., et al. Bruton's tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed/refractory B-cell malignancies. J Clin Oncol 31 (2013), 88–94.
7. MacGlashan, D. Jr., Honigberg, L.A., Smith, A., Buggy, J., Schroeder, J.T., Inhibition of IgE-mediated secretion from human basophils with a highly selective Bruton's tyrosine kinase, Btk, inhibitor. Int Immunopharmacol 11 (2011), 475–479.
8. Chang, B.Y., Huang, M.M., Francesco, M., Chen, J., Sokolove, J., Magadala, P., et al. The Bruton's tyrosine kinase inhibitor PCI-32765 ameliorates autoimmune arthritis by inhibition of multiple effector cells. Arthritis Res Ther, 13, 2011, R115 1-14.
9. Byrd, J.C., Harrington, B., O'Brien, S., Jones, J.A., Schuh, A., Devereux, S., et al. Acalabrutinib (ACP-196) in relapsed chronic lymphocytic leukemia. N Engl J Med 374 (2016), 323–332.